These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 31209511

  • 1. The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative.
    Carbone LD, Vasan S, Prentice RL, Harshfield G, Haring B, Cauley JA, Johnson KC.
    Osteoporos Int; 2019 Oct; 30(10):2039-2056. PubMed ID: 31209511
    [Abstract] [Full Text] [Related]

  • 2. Association of RAAS inhibitors on osteoporosis and fracture risk in the hypertensive population-A prospective population-based cohort study in Lanzhou, China.
    Yin H, Yang M, Sun W, Zhang R, Zhen D, Tang X.
    BMC Musculoskelet Disord; 2024 Oct 09; 25(1):797. PubMed ID: 39385154
    [Abstract] [Full Text] [Related]

  • 3. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
    Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K, Hypertension Outcome, Surveillance Team.
    J Bone Miner Res; 2014 Nov 09; 29(11):2483-8. PubMed ID: 24806397
    [Abstract] [Full Text] [Related]

  • 4. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
    Kwok T, Leung J, Barrett-Connor E, Osteoporotic Fractures in Men (MrOS) Research Group.
    Age Ageing; 2017 Jan 10; 46(1):57-64. PubMed ID: 28181652
    [Abstract] [Full Text] [Related]

  • 5. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
    Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA.
    Eur J Epidemiol; 2017 Nov 10; 32(11):947-959. PubMed ID: 28752198
    [Abstract] [Full Text] [Related]

  • 6. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan.
    Kao YT, Huang CY, Fang YA, Liu JC.
    Int J Cardiol; 2020 Apr 15; 305():147-153. PubMed ID: 31955975
    [Abstract] [Full Text] [Related]

  • 7. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD, Martineau P, Bryanton M, Lix LM.
    Osteoporos Int; 2019 Jul 15; 30(7):1445-1453. PubMed ID: 31016351
    [Abstract] [Full Text] [Related]

  • 8. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
    Hsu WT, Galm BP, Schrank G, Hsu TC, Lee SH, Park JY, Lee CC.
    Hypertension; 2020 Feb 15; 75(2):483-491. PubMed ID: 31838905
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.
    Am J Cardiovasc Drugs; 2019 Jun 15; 19(3):259-286. PubMed ID: 30737754
    [Abstract] [Full Text] [Related]

  • 11. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.
    JACC Heart Fail; 2019 Nov 15; 7(11):970-979. PubMed ID: 31606364
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
    Son M, Seo J, Yang S.
    Hypertension; 2020 Sep 15; 76(3):742-749. PubMed ID: 32654557
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein(a) plasma levels, bone mineral density and risk of hip fracture: a post hoc analysis of the Women's Health Initiative, USA.
    Haring B, Crandall CJ, Carbone L, Liu S, Li W, Johnson KC, Wactawski-Wende J, Shadyab AH, Gass ML, Kamensky V, Cauley JA, Wassertheil-Smoller S.
    BMJ Open; 2019 Apr 24; 9(4):e027257. PubMed ID: 31023762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
    Chan CK, Huang YS, Liao HW, Tsai IJ, Sun CY, Pan HC, Chueh JS, Wang JT, Wu VC, Chu TS, National Taiwan University Hospital Study Group of ARF, the Taiwan Primary Aldosteronism Investigators and the Taiwan Consortium for Acute Kidney Injury and Renal Diseases.
    Hypertension; 2020 Nov 24; 76(5):1563-1571. PubMed ID: 32869673
    [Abstract] [Full Text] [Related]

  • 18. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ, van Vark L, Akkerhuis M, Bertrand M, Fox K, Mourad JJ, Boersma E.
    Int J Cardiol; 2015 Feb 15; 181():425-9. PubMed ID: 25569271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients.
    Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, He H, Wang Z, Ye D, Zhao M, Luo Z, Liu M, Zhang P, Gu J, Liu M, Li D, Liu J, Wan J.
    Hypertension; 2020 Sep 15; 76(3):732-741. PubMed ID: 32654555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.